Targeted Oncology

Targeted Healthcare Communications is at the forefront of the increasing interest in cancer-related products within precision medicine. We proudly hold the distinction of being the first publisher to feature a peer-reviewed journal dedicated to these innovative products. Our offerings include a specialized website, two journals, and a variety of multichannel programs that all concentrate on precision medicine in the field of oncology. Our publication, Targeted Therapies in Oncology™, is committed to equipping oncology healthcare professionals with the latest research, data, and treatment methods related to molecular and immune system targets that can enhance patient outcomes in cancer care. We aim to make the latest developments in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted treatments more accessible for clinical application. The Journal of Targeted Therapies in Cancer™ focuses on elevating cancer patient care by publishing peer-reviewed clinical articles that delve into advancements in cancer targets and targeted therapies, along with their practical applications. Our goal is to broaden oncologists' understanding of biomarkers, pathways, diagnostics, immunotherapy, and targeted therapies, while also providing strategies for personalizing treatment to achieve better patient outcomes. TargetedOnc.com™ is a distinctive resource that emphasizes molecular biology, featuring expert insights on research, management, and treatment. This oncology-centered website is dedicated to providing content that highlights precision medicine in the field. As cancer research shifts towards systems biology and molecular irregularities, many oncologists face the challenge of keeping their knowledge up to date with the evolving landscape of cancer therapeutics.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#360341

United States

#148073

Health/Health Conditions and Concerns

#359

Traffic sources

Monthly visitors

Articles

Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

3 days ago | targetedonc.com | Sabrina Serani

The FDA has granted priority review to the supplemental new drug application (sNDA) of revumenib (Revuforj), an oral, first-in-class Menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutant (mNPM1) acute myeloid leukemia (AML).1This decision underscores the urgent need for novel therapeutic options in this aggressive form of leukemia, which is characterized by high rates of relapse and poor prognosis.
FDA Approves Expanded Gallium Ga-68 Gozetotide Use in mCRPC

3 days ago | targetedonc.com | Sabrina Serani

The FDA has expanded the label for gallium Ga-68 gozetotide (Illuccix) to include patient selection for radioligand therapy (RLT) in the pretaxane setting for metastatic castration-resistant prostate cancer (mCRPC). This approval allows for earlier identification of patients eligible for prostate specific membrane antigen (PSMA)-directed therapies like lutetium Lu-177 vipivotide tetraxetan (Pluvicto), aligning with a shift towards personalized treatment earlier in the disease course.
NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma

4 days ago | targetedonc.com | Sabrina Serani

Findings from the investigator-initiated, noncomparative randomized phase 2 NEO-MEL-T study (NCT04139902) indicate a significant benefit in major pathologic response (MPR) with the addition of a T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitor, cobolimab, to PD-1 monotherapy in high-risk resectable melanoma.1 The study, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by Meghan Mooradian, MD, medical oncologist at Massachusetts General...
Mirvetuximab Active in Platinum-Sensitive Ovarian Cancer Regardless of HRD Status

4 days ago | targetedonc.com | Sabrina Serani

Final data from the phase 2 PICCOLO trial (NCT05041257) demonstrated substantial efficacy in patients with folate receptor alpha (FRα)-positive recurrent platinum-sensitive ovarian cancer (PSOC) treated with mirvetuximab soravtansine-gynx (Elahere), regardless of homologous recombination deficiency (HRD) status).1 These data, presented at the 2025 ESMO Gynecological Cancers Annual Congress, showed that at a median follow-up of 26.6 months, median progression-free survival (PFS) was 6.9 months...
Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors

5 days ago | targetedonc.com | Sabrina Serani

Promising new data from the phase 3 STELLAR-303 pivotal trial (NCT05425940) indicate that zanzalintinib (XL092) in combination with atezolizumab (Tecentriq) significantly improved overall survival (OS) compared with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC).1 This marks a critical advancement in the clinical development program for zanzalintinib, an investigational tyrosine kinase inhibitor (TKI) designed to target various receptor tyrosine...
Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL

5 days ago | targetedonc.com | Sabrina Serani

Pirtobrutinib (Jaypirca) led to improvements in progression-free survival (PFS) and time to next treatment (TTNT) with a favorable tolerability profile when compared with idelalisib (Zydelig) and rituximab (Rituxan; idela-R) and bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) previously treated with covalent Bruton tyrosine kinase inhibitors (cBTKi).
Mismatched Unrelated Donors & PTCy: Better HSCT Outcomes, Expanded Access

5 days ago | targetedonc.com | Sabrina Serani

A phase 2, nonrandomized, multicenter trial (ACCESS; NCT04904588) demonstrated excellent 1-year overall survival (OS) and low rates of severe graft-vs-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)-mismatched unrelated donors (MMUDs).
The Targeted Pulse: A Weekly Dose of Oncology Updates

6 days ago | targetedonc.com | Sabrina Serani

June 22, 2025Fact checked by This week in oncology highlights: FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies. This week in oncology has brought forth a wave of critical developments, underscoring the relentless pursuit of more effective and precise cancer treatments.
Pembrolizumab and Chemoradiation Deliver Durable Responses in Stage III NSCLC

1 week ago | targetedonc.com | Kristi Rosa

The immunotherapy combination of pembrolizumab (Keytruda) plus concurrent chemoradiation therapy (cCRT) continued to deliver durable responses and a manageable safety profile among patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), according to data from the final analysis of the phase 2 KEYNOTE-799 trial (NCT03631784) presented during the 2025 European Lung Cancer Congress.1 In cohort A (n=112), which comprised patients with squamous or nonsquamous...
Atezolizumab Efficacy in Cervical Cancer Consistent Irrespective of PD-L1

1 week ago | targetedonc.com | Sabrina Serani

A post hoc analysis of the pivotal phase 3 BEATcc trial (NCT03556839) has revealed that the clinical benefits of adding atezolizumab (Tecentriq) to standard chemotherapy and bevacizumab (Avastin) in patients with untreated recurrent or metastatic cervical cancer are consistent, irrespective of PD-L1 combined positive score (CPS).